SCHEMBL11705452

SCHEMBL11705452

Cc1cc(NC(=O)c2ccccc2)cc(C)c1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.69
▸ MEN1 O00255 5/20 0.69
▸ FKBP5 Q13451 1/20 0.67
▸ NPC1 O15118 4/20 0.66
▸ RAB9A P51151 4/20 0.66
▸ HTT P42858 2/20 0.64
▸ LMNA P02545 1/20 0.64
▸ GAA P10253 1/20 0.64
▸ SMN1; SMN2 Q16637 2/20 0.61
▸ MAPT P10636 2/20 0.61
▸ KCNK3 O14649 3/20 0.59
▸ KCNK9 Q9NPC2 3/20 0.59
▸ POLB P06746 3/20 0.57
▸ HPGD P15428 1/20 0.56
▸ PTPN1 P18031 1/20 0.55
▸ CACNA1B Q00975 1/20 0.54
▸ APBA1 Q02410 1/20 0.54
▸ THRB P10828 1/20 0.54
▸ P2RX1 P51575 1/20 0.54
▸ SIRT1 Q96EB6 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13210692 0.91 GAA (0.58) KMT2AMEN1FKBP5NPC1RAB9A
SCHEMBL12758272 0.86 NPC1 (0.57) KMT2AMEN1FKBP5NPC1RAB9A
SCHEMBL21625694 0.85 TOP1 (0.52) KMT2AMEN1FKBP5NPC1RAB9A
SCHEMBL10242069 0.83 KMT2A (0.71) KMT2AMEN1FKBP5NPC1RAB9A
SCHEMBL22305399 0.82 KCNK3 (0.83) KMT2AMEN1FKBP5NPC1RAB9A
SCHEMBL28622654 0.82 RAB9A (0.93) KMT2AMEN1FKBP5NPC1RAB9A
SCHEMBL22173521 0.81 THRB (0.73) KMT2AMEN1FKBP5NPC1RAB9A
SCHEMBL3274053 0.81 THRB (0.79) KMT2AMEN1FKBP5NPC1RAB9A
SCHEMBL7295360 0.81 NR1H4 (0.60) KMT2AMEN1NPC1RAB9ALMNA
SCHEMBL27550517 0.80 KMT2A (0.70) KMT2AMEN1FKBP5NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117843521-A Compound serving as thyroid hormone beta receptor agonist as well as preparation method and application thereof 中国药科大学 2024-04-09 — — CN disclosed
US-20200316032-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING RETINAL PIGMENT EPITHELIUM DEGENERATION AND METHODS USING THE SAME THE SCHEPENS EYE RESEARCH, INSTITUTE, INC. 2020-10-08 — — US disclosed
US-4013618-A NITROGEN-CONTAINING STABILIZER TOYOBO CO., LTD. (JA) 1977-03-22 — — US disclosed
US-3957905-A HALOGENATED BISPHENYL COMPOUND, ANTIMONY COMPOUND TOYO BOSEKI KABUSHIKI KAISHA (JA) 1976-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200316032-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING RETINAL PIGMENT EPITHELIUM DEGENERATION AND METHODS USING THE SAME ALDH1A2, RBP4, RBP1 KMT2A 4554/4885MEN1 4710/4885FKBP5 4061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback